ISPOR Announces Real-World Evidence Summit 2023

Published Apr 18, 2023

The Summit Will Be Held May 7, 2023 in Boston, MA, USA

Lawrenceville, NJ, USA—April 18, 2023—ISPOR—The Professional Society for Health Economics and Outcomes Research announced its ISPOR Real-World Evidence Summit 2023 scheduled for May 7 in Boston, MA, USA. The Summit is collocated with and being held immediately prior to the Society’s annual international conference, ISPOR 2023. The Summit is a collaboration between ISPOR, the International Society for Pharmacoepidemiology (ISPE), and the Duke-Margolis Center for Health Policy.

The Summit, themed “Making Real-World Decisions with Real-World Evidence: From Frameworks to Practice,” will take attendees behind the scenes to offer an in-depth examination of key issues surrounding real-world evidence (RWE) in regulatory decisions and health technology assessment. Program sessions, centered around data quality and fit-for-purpose use, will delve into studies that showcase the utilization and effectiveness of RWE in healthcare decision-making.

Sessions for the ISPOR Real-World Evidence Summit 2023 include the following with speakers added to the online program as they are confirmed:

Session 1: From Data Quality to Qualities
The first session of the Summit will examine how data quality is described and measured. Panelists will discuss recent data quality frameworks, developments in validation, and measurement of important aspects of quality. Speakers include:

  • Moderator: Rachele Hendricks-Sturrup, DHSc, MSc, MA; Duke-Margolis Center for Health Policy; Washington, DC, USA
  • Andre Araujo, PhD; GSK; Philadelphia, PA, USA
  • Marni Hall, PhD, MPH; IQVIA; Rockville, MD, USA
  • Sebastian Schneeweiss, MD, ScD; Harvard Medical School, Brigham and Women’s Hospital; Boston, MA, USA

Session 2: Considering Data Qualities in Determining Fit-for-Purpose – Can We Converge on an Approach?
This session will focus on the principles and realities of how fit-for-purpose decisions are made based on the needs of the study question and the qualities of the data. Speakers include:

  • Moderator: Marc Berger, MD; Marc L. Berger, LLC; New York, NY, USA
  • Ana Cochino, BS; EMA; Amsterdam, Netherlands
  • John Concato, MD, MS, MPH; US Food and Drug Administration; Silver Spring, MD, USA
  • Gracy Crane, PhD; Roche Products Limited; Welwyn, England, UK
  • Laurie Lambert, PhD; Canadian Agency for Drugs and Technologies in Health; Ottawa, ON, Canada

Session 3: Transparency in Real-World Evidence: Ensuring Credibility and Confidence
This session will explore how good conduct for RWE studies can offer healthcare decision makers with greater confidence in the credibility of study results. Panelists will cover the use of standardized protocol templates, preregistration of study protocols, and the move towards master protocols, with reference to specific tools that are available or in development. Speakers include:

  • Moderator: Richard Willke, PhD; ISPOR; Lawrenceville, NJ, USA
  • Adam Aten, MPH, MSc; Duke-Margolis Center for Health Policy; Washington, DC, USA
  • C. Daniel Mullins, PhD; University of Maryland School of Pharmacy; Baltimore, MD, USA
  • Shirley Wang, PhD, MSc; Brigham and Women’s Hospital, Harvard Medical School; Boston, MA, USA

Session 4: Navigating the Real-World Evidence Landscape – Successes, Struggles, and the Path Forward
This final session of the Summit will include a review of specific cases of RWE use for regulatory or health technology assessment purposes. Panelists will consider both data and analytic issues in their discussions. Speakers include:

  • Moderator: Nancy Dreyer, MPH, PhD; IQVIA Real World Solutions; Chapel Hill, NC, USA
  • Stephen Duffield, PhD, MD; NICE; Liverpool, England, UK
  • Wim Goettsch, PhD; National Health Care Institute (ZIN) and Utrecht University; Diemen, Netherlands
  • Ashley Jaksa, MPH; Aetion, Inc; Boston, MA, USA
  • Tae Hyun Jung, PhD; Center for Drug Evaluation and Research, US Food and Drug Administration; Rockville, MD, USA

The ISPOR Real-World Evidence Summit 2023 is collocated with and being held immediately prior to ISPOR 2023, the Society’s annual international conference. ISPOR 2023 is scheduled for May 7-10 with the theme, “Impacting Innovation, Value, and Healthcare Decision Making.” ISPOR 2023 requires a separate registration.

ISPOR is recognized globally as the leading professional society for health economics and outcomes research and for its role in improving healthcare decisions. ISPOR Summits draw healthcare stakeholders with an interest in HEOR-related topics, including researchers and academicians, assessors and regulators, payers and policymakers, the life sciences industry, healthcare providers, and patient engagement organizations.

Additional information on the conference can be found at:
Summit Information | Program | Press


ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Website  | LinkedIn  | Twitter (@ispororg)  |  YouTube  |  Facebook  |  Instagram

Explore Related HEOR by Topic

Related Stories

ISPOR Announces Patient-Centered Research Summit 2024

Apr 23, 2024

ISPOR announced the sessions and speakers for its Patient-Centered Research Summit 2024. The Summit is scheduled to be held May 5 in Atlanta, GA, USA and is co-located with the Society’s annual international conference, ISPOR 2024.

ISPOR Summit 2021 to Focus on Value Assessment

May 24, 2021

ISPOR announced its upcoming ISPOR Summit 2021: Value Assessment. The Summit is themed “Value Assessment: New Insights, Approaches, and Applications” and will be held on June 10.

ISPOR-FDA Summit 2020 Will Focus on the Use of Patient-Preference Information in Medical Devices

Jan 28, 2020

ISPOR announced that it will be holding a joint ISPOR-FDA Summit, “Using Patient-Preference Information in Medical Device Regulatory Decisions: Benefit-Risk and Beyond,” on March 31, 2020 in Silver Spring, MD, USA.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now